Monte Financial Group LLC Purchases 43,740 Shares of Pfizer Inc. (NYSE:PFE)

Monte Financial Group LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 21.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 252,067 shares of the biopharmaceutical company's stock after purchasing an additional 43,740 shares during the period. Pfizer makes up 2.6% of Monte Financial Group LLC's investment portfolio, making the stock its 10th largest holding. Monte Financial Group LLC's holdings in Pfizer were worth $6,387,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at about $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer in the 4th quarter worth about $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE opened at $23.97 on Friday. The firm has a market cap of $136.27 billion, a P/E ratio of 17.37, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $23.26 and its 200-day moving average is $24.90. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the business earned $0.82 EPS. Pfizer's revenue was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.18%. The ex-dividend date was Friday, May 9th. Pfizer's payout ratio is 124.64%.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.